Vital Therapies (NASDAQ:VTL) is set to release its earnings data after the market closes on Monday, March 5th. Analysts expect Vital Therapies to post earnings of ($0.31) per share for the quarter.

Vital Therapies (NASDAQ:VTL) opened at $5.10 on Friday. Vital Therapies has a 1 year low of $2.25 and a 1 year high of $6.70.

In other Vital Therapies news, Director Muneer A. Satter purchased 50,000 shares of Vital Therapies stock in a transaction on Thursday, December 7th. The shares were bought at an average price of $4.77 per share, with a total value of $238,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter purchased 100,000 shares of Vital Therapies stock in a transaction on Wednesday, December 13th. The stock was acquired at an average cost of $5.48 per share, for a total transaction of $548,000.00. The disclosure for this purchase can be found here. Insiders acquired 300,000 shares of company stock worth $1,520,000 in the last ninety days. Insiders own 32.60% of the company’s stock.

Several brokerages have weighed in on VTL. BidaskClub lowered shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Raymond James Financial restated a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Finally, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, November 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Vital Therapies presently has a consensus rating of “Hold” and an average price target of $6.00.

TRADEMARK VIOLATION WARNING: “Vital Therapies (VTL) to Release Quarterly Earnings on Monday” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Earnings History for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with's FREE daily email newsletter.